NCT07595809 Dietary Intervention and Physical Activity in Patients With Heart Failure and Reduced Ejection Fraction
| NCT ID | NCT07595809 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Medical University of Silesia |
| Condition | Heart Failure With Reduced Ejection Fraction |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2023-05-08 |
| Primary Completion | 2026-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2023-05-08 with a primary completion date of 2026-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Heart failure with reduced ejection fraction (HFrEF) is frequently associated with abnormalities in body composition, including reduced skeletal muscle mass and sarcopenia, which are independent predictors of reduced exercise tolerance, impaired quality of life, and increased mortality. Despite advances in pharmacological therapy, evidence-based non-pharmacological strategies aimed at preventing muscle mass loss remain limited. This randomized controlled trial aims to evaluate the effects of dietary intervention based on the DASH diet with high-protein elements, resistance exercise training, and their combination on skeletal muscle mass, functional capacity, echocardiographic parameters, biochemical markers, and quality of life in patients with HFrEF.
Eligibility Criteria
Inclusion Criteria: Written informed consent obtained prior to participation Age \>30 years Diagnosis of chronic heart failure, NYHA functional class I-III Left ventricular ejection fraction \<40% Exclusion Criteria: NYHA functional class IV heart failure Potentially reversible cause of heart failure Estimated glomerular filtration rate \<30 mL/min Severe anemia (hemoglobin \<9 g/dL) Uncontrolled thyroid disease Severe hepatic dysfunction History of hyperkalemia or hyperkalemia at baseline Epilepsy Presence of joint endoprostheses Gastrointestinal disorders limiting adherence to the DASH diet Physical limitations precluding participation in structured exercis
Frequently Asked Questions
Who can join the NCT07595809 clinical trial?
This trial is open to participants of all sexes, aged 30 Years or older, studying Heart Failure With Reduced Ejection Fraction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07595809 currently recruiting?
Yes, NCT07595809 is actively recruiting participants. Visit ClinicalTrials.gov or contact Medical University of Silesia to inquire about joining.
Where is the NCT07595809 trial being conducted?
This trial is being conducted at Zabrze, Poland.
Who is sponsoring the NCT07595809 clinical trial?
NCT07595809 is sponsored by Medical University of Silesia. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.